Socium’s leadership team and advisory board members have decades of experience in immunotherapy, vaccine development, translational research, clinical program implementation and intellectual property protection.
July 2, 2018 -- Today, Socium Therapeutics announced that Joachim Fensterle, PhD has joined the company's Scientific Advisory Board. After receiving his PhD in immunology / infection biology from the Max Planck Institute for Infection Biology, Dr. Fensterle moved to...
June 23, 2018 -- Today, Socium Therapeutics announced that Debasish Roychowdhury, PhD has joined the company's Scientific Advisory Board. Dr. Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management...
Socium Therapeutics finalizes acquisition of Oral Allogenic Immunotherapy Platform from Aeterna Zentaris
June 1, 2018 -- Socium Therapeutics, Inc. ("Socium") announced that it had finalized the acquisition of Aeterna Zentaris' live recombinant oral allogenic immunotherapy platform ("Platform"), including AEZS-120, the most advanced product candidate for prostate cancer...
90 E. Halsey Road
Parsippany, NJ 07054